Short Interest in Aptevo Therapeutics Inc. (NASDAQ:APVO) Declines By 46.2%

Aptevo Therapeutics Inc. (NASDAQ:APVO) was the recipient of a large decrease in short interest during the month of February. As of February 15th, there was short interest totalling 23,500 shares, a decrease of 46.2% from the January 31st total of 43,700 shares. Approximately 1.6% of the company’s stock are short sold. Based on an average daily volume of 197,200 shares, the days-to-cover ratio is currently 0.1 days.

Aptevo Therapeutics Price Performance

Shares of NASDAQ APVO traded down $0.73 during mid-day trading on Monday, hitting $3.09. The stock had a trading volume of 146,443 shares, compared to its average volume of 142,888. The company has a 50 day moving average of $4.26 and a two-hundred day moving average of $207.14. Aptevo Therapeutics has a twelve month low of $3.01 and a twelve month high of $399.60.

Analyst Upgrades and Downgrades

Separately, StockNews.com initiated coverage on Aptevo Therapeutics in a research report on Monday, December 9th. They issued a “sell” rating for the company.

Aptevo Therapeutics Company Profile

Aptevo Therapeutics Inc, a clinical-stage research and development biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. It develops its products using ADAPTIR and ADAPTIR-FLEX platforms to generate monospecific, bispecific, and multi-specific antibody candidates capable of enhancing the human immune system against cancer cells.